For: | Vento P, Mustonen H, Joensuu T, Kärkkäinen P, Kivilaakso E, Kiviluoto T. Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer. World J Gastroenterol 2007; 13(21): 2945-2951 [PMID: 17589944 DOI: 10.3748/wjg.v13.i21.2945] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v13/i21/2945.htm |
Number | Citing Articles |
1 |
Alison Bradley, Robert Van Der Meer, Sunil Krishnan. Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis. PLOS ONE 2019; 14(2): e0212805 doi: 10.1371/journal.pone.0212805
|
2 |
Youyao Xu, Yizhen Chen, Fang Han, Jia Wu, Yuhua Zhang. Neoadjuvant therapy <i>vs</i>. upfront surgery for resectable pancreatic cancer: An update on a systematic review and meta-analysis. BioScience Trends 2021; 15(6): 365 doi: 10.5582/bst.2021.01459
|
3 |
K Rangarajan, PH Pucher, T Armstrong, A Bateman, ZZR Hamady. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis. The Annals of The Royal College of Surgeons of England 2019; 101(7): 453 doi: 10.1308/rcsann.2019.0060
|
4 |
Jerome Martin Laurence, Peter Duy Tran, Kavita Morarji, Guy D. Eslick, Vincent Wai To Lam, Charbel Sandroussi. A Systematic Review and Meta-analysis of Survival and Surgical Outcomes Following Neoadjuvant Chemoradiotherapy for Pancreatic Cancer. Journal of Gastrointestinal Surgery 2011; 15(11): 2059 doi: 10.1007/s11605-011-1659-7
|
5 |
Wei Liu, Xue-Liang Fu, Jian-Yu Yang, De-Jun Liu, Jiao Li, Jun-Feng Zhang, Yan-Miao Huo, Min-Wei Yang, Rong Hua, Yong-Wei Sun. Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma. Medicine 2016; 95(15): e3009 doi: 10.1097/MD.0000000000003009
|
6 |
Angelo Andriulli, Virginia Festa, Edoardo Botteri, Maria R. Valvano, Maurizio Koch, Claudio Bassi, Patrick Maisonneuve, Pierluigi Di Sebastiano. Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies. Annals of Surgical Oncology 2012; 19(5): 1644 doi: 10.1245/s10434-011-2110-8
|
7 |
Olga N. Tucker, Mohamed Rela. Controversies in the Management of Borderline Resectable Proximal Pancreatic Adenocarcinoma with Vascular Involvement. HPB Surgery 2008; 2008: 1 doi: 10.1155/2008/839503
|
8 |
Juan Manuel Sendra Gutiérrez, Matilde Palma Ruiz, Antonio Sarría Santamera, María Puerto Vázquez. Manejo hospitalario del cáncer de páncreas en España y estudio de los factores asociados a la mortalidad intrahospitalaria. Gastroenterología y Hepatología 2008; 31(6): 319 doi: 10.1157/13123598
|
9 |
Katia T. Papalezova, Douglas S. Tyler, Dan G. Blazer, Bryan M. Clary, Brian G. Czito, Herbert I. Hurwitz, Hope E. Uronis, Theodore N. Pappas, Christopher G. Willett, Rebekah R. White. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?. Journal of Surgical Oncology 2012; 106(1): 111 doi: 10.1002/jso.23044
|
10 |
Chengfang Wang, Yingsheng Wu, Weilin Wang. Neoadjuvant therapy for resectable pancreatic cancer: a narrative review. Journal of Pancreatology 2022; 5(2): 69 doi: 10.1097/JP9.0000000000000091
|
11 |
Giuliano Barugola, Stefano Partelli, Stefano Marcucci, Nora Sartori, Paola Capelli, Claudio Bassi, Paolo Pederzoli, Massimo Falconi. Resectable Pancreatic Cancer: Who Really Benefits From Resection?. Annals of Surgical Oncology 2009; 16(12): 3316 doi: 10.1245/s10434-009-0670-7
|
12 |
Suzanne C. Schiffman, Carrie K. Chu, Jaemin Park, Maria Russell, Steven Keilin, David A. Kooby, Charles R. Scoggins, Kelly M. McMasters, Robert C.G. Martin. Is prior cholecystectomy associated with decreased survival in patients with resectable pancreatic adenocarcinoma following pancreaticoduodenectomy?. The American Journal of Surgery 2011; 201(4): 519 doi: 10.1016/j.amjsurg.2010.02.004
|
13 |
Carolin Zimmermann, Gunnar Folprecht, Daniel Zips, Christian Pilarsky, Hans Detlev Saeger, Robert Grutzmann. Neoadjuvant Therapy in Patients with Pancreatic Cancer: A Disappointing Therapeutic Approach?. Cancers 2011; 3(2): 2286 doi: 10.3390/cancers3022286
|
14 |
HIDEHIRO TAJIMA, TETSUO OHTA, HIROHISA KITAGAWA, KOICHI OKAMOTO, SEISHO SAKAI, ISAMU MAKINO, JUN KINOSHITA, HIROYUKI FURUKAWA, KEISHI NAKAMURA, HIRONORI HAYASHI, KATSUNOBU OYAMA, MASAFUMI INOKUCHI, HISATOSHI NAKAGAWARA, HIDETO FUJITA, HIROYUKI TAKAMURA, ITASU NINOMIYA, SACHIO FUSHIDA, TAKASHI TANI, TAKASHI FUJIMURA, HIROKO IKEDA, SEIKO KITAMURA. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. Experimental and Therapeutic Medicine 2012; 3(5): 787 doi: 10.3892/etm.2012.482
|
15 |
Stephanie L. Goff, John A. Chabot. A Neoadjuvant Strategy for the Management of Nonmetastatic Pancreatic Cancer. The Cancer Journal 2012; 18(6): 602 doi: 10.1097/PPO.0b013e318279aade
|
16 |
HIDEHIRO TAJIMA, HIROHISA KITAGAWA, TOMOYA TSUKADA, SHINICH NAKANUMA, KOICHI OKAMOTO, SEISHO SAKAI, ISAMU MAKINO, HIROYUKI FURUKAWA, KEISHI NAKAMURA, HIRONORI HAYASHI, KATSUNOBU OYAMA, MASAFUMI INOKUCHI, HISATOSHI NAKAGAWARA, TOMOHARU MIYASHITA, HIDETO FUJITA, HIROSHI ITOH, HIROYUKI TAKAMURA, ITASU NINOMIYA, SACHIO FUSHIDA, TAKASHI FUJIMURA, TETSUO OHTA. A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer. Molecular and Clinical Oncology 2013; 1(4): 768 doi: 10.3892/mco.2013.133
|
17 |
Megan Winner, Stephanie L. Goff, John A. Chabot. Neoadjuvant therapy for Non-metastatic Pancreatic Ductal Adenocarcinoma. Seminars in Oncology 2015; 42(1): 86 doi: 10.1053/j.seminoncol.2014.12.008
|
18 |
Terence C. Chua, Akshat Saxena. Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: A review of current results. Surgical Oncology 2011; 20(4): e161 doi: 10.1016/j.suronc.2011.05.003
|
19 |
Alison Bradley, Robert Van Der Meer. Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-40951-6
|
20 |
Bohan Yang, Kai Chen, Weikang Liu, Di Long, Yingjin Wang, Xinxin Liu, Yongsu Ma, Xiaodong Tian, Yinmo Yang. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis. Clinical and Experimental Medicine 2023; 23(7): 3159 doi: 10.1007/s10238-023-01112-2
|
21 |
Richard K. Orr. Outcomes in Pancreatic Cancer Surgery. Surgical Clinics of North America 2010; 90(2): 219 doi: 10.1016/j.suc.2009.12.007
|
22 |
Sivesh K. Kamarajah, James R. Bundred, Charles Boyle, June Oo, Sanjay Pandanaboyana, Benjamin Loveday. Impact of neoadjuvant therapy on post‐operative pancreatic fistula: a systematic review and meta‐analysis. ANZ Journal of Surgery 2020; 90(11): 2201 doi: 10.1111/ans.15885
|
23 |
Si-qi Yang, Rui-qi Zou, Yu-shi Dai, Fu-yu Li, Hai-jie Hu. Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis. Updates in Surgery 2024; 76(1): 1 doi: 10.1007/s13304-023-01626-0
|
24 |
Yoon Suk Lee, Jong-Chan Lee, Se Yeol Yang, Jaihwan Kim, Jin-Hyeok Hwang. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-52167-9
|
25 |
Jason W. Denbo, Morgan L. Bruno, Jordan M. Cloyd, Laura Prakash, Jeffrey E. Lee, Michael Kim, Christopher H. Crane, Eugene J. Koay, Sunil Krishnan, Prajnan Das, Bruce D. Minsky, Gauri Varadhachary, Rachna Shroff, Robert Wolff, Milind Javle, Michael J. Overman, David Fogelman, Thomas A. Aloia, Jean-Nicolas Vauthey, Jason B. Fleming, Matthew H. G. Katz. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Journal of Gastrointestinal Surgery 2016; 20(12): 1975 doi: 10.1007/s11605-016-3286-9
|
26 |
Katherine S. Cools, Hanna K. Sanoff, Hong Jin Kim, Jen Jen Yeh, Karyn B. Stitzenberg. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy. Journal of Surgical Oncology 2018; 118(3): 455 doi: 10.1002/jso.25183
|
27 |
Hisato Igarashi, Tetsuhide Ito, Ken Kawabe, Terumasa Hisano, Yoshiyuki Arita, Toyoma Kaku, Ryoichi Takayanagi. Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. World Journal of Gastroenterology 2008; 14(34): 5311-5315 doi: 10.3748/wjg.14.5311
|
28 |
Christopher Ryan Deig, Thomas Lee Sutton, Blake Beneville, Kristin Trone, Amanda Stratton, Ali N. Gunesch, Amy Ivy Liu, Alaaeddin Alrohaibani, Maedeh Mohebnasab, Solange Bassale, Alison Grossblatt-Wait, Dove Keith, Fouad Attia, Erin W. Gilbert, Charles D. Lopez, Adel Kardosh, Emerson Y. Chen, Kenneth G. Bensch, Nima Nabavizadeh, Charles R. Thomas, Skye C. Mayo, Brett C. Sheppard, Aaron Grossberg. Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications. Cancers 2022; 14(3): 609 doi: 10.3390/cancers14030609
|
29 |
Raphael L. C. Araujo, Raphael O. Silva, Cristiano de Pádua Souza, Jean M. Milani, Florence Huguet, Ana C. Rezende, Sebastien Gaujoux. Does neoadjuvant therapy for pancreatic head adenocarcinoma increase postoperative morbidity? A systematic review of the literature with meta‐analysis. Journal of Surgical Oncology 2020; 121(5): 881 doi: 10.1002/jso.25851
|
30 |
C. P. Xu, X. J. Xue, N. Liang, D. G. Xu, F. J. Liu, X. S. Yu, J. D. Zhang. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology 2014; 140(4): 549 doi: 10.1007/s00432-013-1572-4
|
31 |
Feng Cao, Jia Li, Ang Li, Fei Li. Radical antegrade modular pancreatosplenectomy versus standard procedure in the treatment of left-sided pancreatic cancer: A systemic review and meta-analysis. BMC Surgery 2017; 17(1) doi: 10.1186/s12893-017-0259-1
|
32 |
Hidetoshi Eguchi, Osamu Ishikawa, Hiroaki Ohigashi, Hidenori Takahashi, Masahiko Yano, Kinji Nishiyama, Yasuhiko Tomita, Rie Uehara, Akio Takehara, Yusuke Nakamura, Hidewaki Nakagawa. Serum REG4 Level Is a Predictive Biomarker for the Response to Preoperative Chemoradiotherapy in Patients With Pancreatic Cancer. Pancreas 2009; 38(7): 791 doi: 10.1097/MPA.0b013e3181ac5337
|
33 |
Brooke Glessing, Shawn Mallery. Endoscopic Ultrasonography. 2016; : 151 doi: 10.1002/9781118781067.ch18
|